Adding topiramate to valproate therapy may cause reversible hepatic failure.
The authors report a 51-year-old women with pharmacoresistant partial epilepsy who tolerated well valproate monotherapy and in combination with several other antiepileptic drugs, but developed symptoms and signs of reversible hepatic failure under a combination of valproate and topiramate. Symptoms resolved after discontinuation of VPA. This case provides further anecdotal evidence that topiramate may increase the risk of liver failure when given in combination with other potentially hepatotoxic antiepileptic drugs.
Bumb
Anja
A
Neurosciences Department University Hospital of Luxemboug, Luxembourg.
Diederich
Nico
N
Beyenburg
Stefan
S
D000927:Anticonvulsants / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000503:physiopathology*; D004359:Drug Therapy, Combination; D004828:Epilepsies, Partial / Q000150:complications* / Q000188:drug therapy; D005260:Female; D005632:Fructose / Q000009:adverse effects* / Q000031:analogs & derivatives*; D006801:Humans; D002532:Intracranial Aneurysm / Q000601:surgery; D008111:Liver Function Tests; D008875:Middle Aged; D011183:Postoperative Complications; D000077236:Topiramate; D014635:Valproic Acid / Q000009:adverse effects*
D000927:Anticonvulsants; D000077236:Topiramate; D005632:Fructose; D014635:Valproic Acid